ECSP045087A - Nueva formulación de jarabe de epinastina seco y acuoso - Google Patents

Nueva formulación de jarabe de epinastina seco y acuoso

Info

Publication number
ECSP045087A
ECSP045087A EC2004005087A ECSP045087A ECSP045087A EC SP045087 A ECSP045087 A EC SP045087A EC 2004005087 A EC2004005087 A EC 2004005087A EC SP045087 A ECSP045087 A EC SP045087A EC SP045087 A ECSP045087 A EC SP045087A
Authority
EC
Ecuador
Prior art keywords
epinastine
syrup
dry
water
new formulation
Prior art date
Application number
EC2004005087A
Other languages
English (en)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of ECSP045087A publication Critical patent/ECSP045087A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)

Abstract

La presente invención se refiere a una nueva formulación de epinastina en forma de polvo (jarabe seco) para ser mezclada con agua antes de usarse. La epinastina puede usarse como base libre o bien como sal de la misma aceptable farmacéuticamente. La epinastina, entre otras cosas, se aplica al tratamiento de alergias, dolor, en particular el dolor crónico y el dolor producido por una inflamación, la migraña, el asma, la rinitis, la conjuntivitis y/o la bronquitis. En particular, la formulación es para el tratamiento de alergias, dermatitis, rinitis, conjuntivitis, bronquitis y asma.
EC2004005087A 2001-10-26 2004-04-26 Nueva formulación de jarabe de epinastina seco y acuoso ECSP045087A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10152973A DE10152973A1 (de) 2001-10-26 2001-10-26 Neue trockene und wässrige Epinastin-Sirup-Formulierung

Publications (1)

Publication Number Publication Date
ECSP045087A true ECSP045087A (es) 2004-06-28

Family

ID=7703856

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2004005087A ECSP045087A (es) 2001-10-26 2004-04-26 Nueva formulación de jarabe de epinastina seco y acuoso

Country Status (9)

Country Link
EP (1) EP1448204A1 (es)
JP (2) JP4564749B2 (es)
KR (1) KR20050034619A (es)
BR (1) BR0213488A (es)
CO (1) CO5580751A2 (es)
DE (1) DE10152973A1 (es)
EC (1) ECSP045087A (es)
MX (1) MXPA04003772A (es)
WO (1) WO2003037350A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1452177A1 (en) * 2003-02-27 2004-09-01 Boehringer Ingelheim International GmbH Pharmaceutical formulations comprising sodium laurylsulfate as bitterness masking agent
US20040247686A1 (en) * 2003-04-04 2004-12-09 Boehringer Ingelheim International Gmbh Pharmaceutical compositions comprising epinastine for the treatment of skin diseases
JP2007530481A (ja) * 2004-03-24 2007-11-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング エピナスチン及び１又は２以上の追加のミネラル又は１又は２以上の生薬のコンビネーションを含む皮膚疾患の治療用医薬組成物
JP5132090B2 (ja) * 2006-06-16 2013-01-30 東和薬品株式会社 塩酸エピナスチンドライシロップ剤
CN105708808B (zh) * 2014-12-01 2018-11-27 重庆安格龙翔医药科技有限公司 一种盐酸依匹斯汀颗粒剂及其制备方法
CN105708840A (zh) * 2014-12-01 2016-06-29 重庆安格龙翔医药科技有限公司 一种盐酸依匹斯汀组合物
CN105708807B (zh) * 2014-12-01 2018-11-27 重庆安格龙翔医药科技有限公司 一种盐酸依匹斯汀细粒剂的制备方法
JP7599838B2 (ja) * 2019-04-10 2024-12-16 参天製薬株式会社 エピナスチン又はその塩を含有する水性医薬組成物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3008944A1 (de) * 1980-03-08 1981-09-24 C.H. Boehringer Sohn, 6507 Ingelheim Dibenzimidazoazepine, ihre herstellung und verwendung
EP0658340A1 (en) * 1993-12-17 1995-06-21 Unilever N.V. Oral compositions
JPH0827034A (ja) * 1994-07-14 1996-01-30 Nikken Chem Co Ltd エリスリトール含有内用液剤
JPH0952849A (ja) * 1995-06-06 1997-02-25 Taisho Pharmaceut Co Ltd 感冒剤用組成物
DE19542281C2 (de) * 1995-11-14 1997-12-04 Boehringer Ingelheim Kg Verwendung von Epinastin für die Behandlung der Migräne
JPH1045576A (ja) * 1996-08-05 1998-02-17 Taisho Pharmaceut Co Ltd 鼻炎用内服薬
EP1020193A4 (en) * 1997-09-30 2006-05-24 Daiichi Seiyaku Co ORAL PREPARATION
JPH11302189A (ja) * 1998-04-21 1999-11-02 Taisho Pharmaceut Co Ltd 感冒用組成物
JP4731777B2 (ja) * 1999-10-12 2011-07-27 マルホ株式会社 経口医薬組成物

Also Published As

Publication number Publication date
EP1448204A1 (en) 2004-08-25
BR0213488A (pt) 2004-11-03
WO2003037350A1 (en) 2003-05-08
MXPA04003772A (es) 2004-07-30
KR20050034619A (ko) 2005-04-14
JP2005508364A (ja) 2005-03-31
CO5580751A2 (es) 2005-11-30
JP2010132702A (ja) 2010-06-17
DE10152973A1 (de) 2003-05-08
JP4564749B2 (ja) 2010-10-20

Similar Documents

Publication Publication Date Title
BR0314603A (pt) Uso de inibidores da sìntese de citoquina para o tratamento de distúrbios de olhos secos
IL158559A (en) Use of 5-lipoxygenase inhibitors for the preparation of a pharmaceutical composition for treating acne
CR10167A (es) "uso de derivados de sulfamida heterociclica benzo-fusionada para el tratamiento de dolor"
ECSP045087A (es) Nueva formulación de jarabe de epinastina seco y acuoso
MX2009010761A (es) Formas cristalinas de 6-[2-(metilcarbamoil)fenilsulfanil]-3-e-[2-( piridin-2-il)etenil]indzol adecuadas para el tratamiento del crecimiento celular anormal en mamiferos.
DK1523335T3 (da) Injicerbar depotformulering omfattende iloperidonkrystaller
EP1569684A4 (en) USE OF HMGB FRAGMENTS AS ANTI-INFLAMMATORY AGENTS
BR0313629B1 (pt) composiÇço detergente bifÁsica lÍquida aquosa de limpeza pessoal.
ES2570599T3 (es) Composición suave para desinfección cutánea
PA8525001A1 (es) Compuestos de 1,4-dihidropiridina como antagonistas de bradicinina
BR9903973A (pt) Novidade para sobremesa congelada
AR054833A1 (es) Formas de dosificacion de liberacion retardada oral altamemte biodisponibles de succinato de o-desmetilvenlafaxina
ATE419038T1 (de) Formulierungen enthaltend melatonin, ginkgo biloba und biotin
MD4093B1 (ro) Utilizare a compoziţiei farmaceutice topice cu conţinut de ambroxol
PA8613001A1 (es) Derivados de triazol sustituidos como antagonistas de oxitocina
PA8562001A1 (es) Brivudina estabilizada en formulaciones topicas
AU2002243451A1 (en) Use of catecholamine reuptake inhibitors to enhance memory
IS6426A (is) Píperasínómetýlbensamíð sem delta-ópíóíðviðtakagerandefni
AU2002226060A1 (en) Compositions containing gangliosides for use in the treatment of skin disorders
AR034910A1 (es) Composicion de barra de jabon/detergente y procedimiento de fabricacion
CO5261624A1 (es) Novedosos derivados fenilheteroalquilamina, procesos para su preparacion, composiciones farmaceuticas que comprenden dichos derivados novedosos y su uso en terapia
AR031720A1 (es) Benzimidazoles n-alcoxialquil sustituidos, proceso para su preparacion, composiciones, y uso de estos compuestos para preparar composiciones antiparasitarias
BRPI0511125A (pt) usos de ácido 5,6,7-triidroxieptanóico seus e análogos
SE0102640D0 (sv) Novel compounds
SE0202280D0 (sv) Novel compounds